In the intricate world of pharmaceutical synthesis, the quality of intermediate compounds dictates the success of the final active pharmaceutical ingredient (API). Triazole derivatives, a class of heterocyclic organic compounds, are frequently employed as versatile building blocks in drug development due to their unique chemical properties and biological activities.

One such significant compound is (1R,3S,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane, identified by CAS number 423165-07-5. This molecule is a critical precursor in the production of Maraviroc, an essential medication for managing HIV infection. The demand for high purity in this intermediate is non-negotiable, as even trace impurities can affect the therapeutic outcome of the drug. NINGBO INNO PHARMCHEM CO.,LTD. specializes in manufacturing such advanced chemical intermediates, ensuring they meet the demanding standards of the pharmaceutical industry.


The structural complexity of this triazole derivative provides a solid foundation for the multi-step synthesis required for complex APIs. Its consistent availability and reliable quality are key factors for pharmaceutical companies aiming for efficient and cost-effective Maraviroc production. We pride ourselves on being a trusted supplier in China, providing these crucial building blocks that empower our clients' research and manufacturing processes. The strategic procurement of pharmaceutical intermediates like CAS 423165-07-5 directly impacts the speed and success of bringing new therapies to market.


NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to advancing pharmaceutical synthesis through the provision of superior quality chemical intermediates. Our commitment to excellence in producing compounds like (1R,3S,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane supports the global effort to develop and distribute life-saving medicines. We offer these essential materials to foster innovation and efficiency in drug manufacturing, reinforcing our position as a key partner in the pharmaceutical supply chain.